AbbVie’s Mavyret (glecaprevir and pibrentasvir) Receives FDA’s Approval for All Genotypes of Hepatitis C in Pediatric Patients

 AbbVie’s Mavyret (glecaprevir and pibrentasvir) Receives FDA’s Approval for All Genotypes of Hepatitis C in Pediatric Patients

AbbVie’s Mavyret (glecaprevir and pibrentasvir) Receives FDA’s Approval for All Genotypes of Hepatitis C in Pediatric Patients

Shots:

  • The approval follows the clinical study results assessing Mavyret (glecaprevir & pibrentasvir) in 47 children aged 12-17 yrs. with genotype 1, 2, 3 or 4 HCV infection without/mild Cirrhosis resulted in no virus detection @12wks. after receiving Mavyret for 8/16wks.
  • The study assessing Mavyret in pediatric patients with cirrhosis/history of a kidney or liver transplant/genotype 5 or 6 HCV infection, safety & efficacy follows the clinical study conducted in adults in 2017
  • Mavyret is an oral combination therapy of glecaprevir (ABT-493, broad-genotypic NS3/4A protease inhibitor) and pibrentasvir (ABT-530, NS5A inhibitor) and has received FDA’s PR & BT designation for HCV in adults

Click here to read full press release/ article | Ref: The US FDA | Image: Cystic Fibrosis News Today

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post